ImmuCell reports Q4 2023 product sales of $5.1M, up 30% YoY; backlog grows to $9.4M

IMMUCELL CORP /DE/

2023-FY EPS reported -$0.75 revenue$17,471,669

Q4 2023 sales $5.1M vs $3.9M in Q4 2022 (+30.3%); full-year 2023 sales $17.5M vs $18.6M (-5.9%).
Backlog $9.4M as of Dec 31, 2023, up from $2.5M a year ago, driven by production disruptions from contamination events.
Production output improved in Nov/Dec 2023, annualizing ~$26.8M; company targeting >$6M quarterly production.
FDA response on Re-Tain CMC Technical Section expected by May 2024.
Conference call to discuss full results on Feb 22, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

IMMUCELL CORP /DE/ reported preliminary financial results for the fourth quarter of 2023, which ended December 31, 2023.

Period: the fourth quarter of 2023, which ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

IMMUCELL CORP /DE/ reported preliminary financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001213900-24-001894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.